Solu Therapeutics is developing precision-medicine therapeutics that eliminate cells driving oncology, inflammatory and autoimmune diseases. Antibodies can be modified to kill the cells they recognise. To identify membrane proteins expressed on disease-driving cells, Solu is using their proprietary Cytotoxicity Targeting Chimera platform that unlocks antibody-intractable cell surface targets providing the capability to develop next-generation medicines. The platform involves identifying new tumor-associated antigens to eliminate cancer cells, depleting pathogenic immune cells and extending the half-life of small molecular antagonists and agonists.

Solu Therapeutics

Drug notes:

About:

Jobs: